Pharmaceutical giants to join forces in battle against cancer
Another day, another cancer immunotherapy arrangement. In this instance, Pfizer and Merck & Co are joining forces to research the potential of another combination of two of their drugs. The two firms have said they will explore the therapeutic potential of marrying Pfizer’s Xalkori (crizontinib) with